Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities
SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader and more diverse therapeutic landscape. Viva Biotech has responded by building an integrated pharmacology pl...
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up ...
Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical R&D ecosystem. SHANGHAI, Sept. 29, 2025 /PRNewswire/ -- Viva Biotech announced today that it has been honored...
Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights
SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge the gap between small molecules and large biologics. Positioned between the two, cyclic peptides combine...
Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection
SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings ("Viva Biotech"), underwent a cGMP (Current Good Manufacturing Practices) on-site inspection by the U.S. Food and Drug Administration (...
Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D
Highlights of Annual Results for the Year Ended December 31, 2024 Revenue reached RMB1,986.7 million Gross profit amounted to RMB687.4 million Net profit recorded RMB222.0 million, a significant turnaround from a year ago Adjusted Non-IFRS net profit recorded RMB314.6 million, a YOY increase of nea...
Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion
HONG KONG, Dec. 11, 2024 /PRNewswire/ -- Recently, Viva Biotech Holdings Group ("Viva Biotech") announced the official establishment of its new branch inBoston ,USA. As a global leader in drug research, development and manufacturing services, this milestone marks a significant step forward in the ...
Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms
Results Highlights for Interim Results ended 30 June 2024 Revenue reached RMB981.8 million Gross profit amounted to RMB339.1 million Net profit grew by 956.0 YoY to RMB144.2 million Adjusted non-IFRS net profit reached RMB168.2 million, increased by 15.1% YoY HONG KONG, Aug. 29, 2024 /PRNewswire/ ...
Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future
Highlights of the Annual Results as of December 31, 2023: Revenue reached RMB2,155.6 million Gross profit amounted to RMB738.5 million Adjusted non-IFRS net loss improved to RMB208.8 million, representing a significant turnaround from a negative position compared to the corresponding period of las...
Viva Biotech Secures Approximately US$ 210 Million Funding
HONG KONG, Nov. 20, 2023 /PRNewswire/ -- On November 20, 2023, Viva Biotech Holdings Group (1873. HK) announced thatit completed a funding round, securing approximatelyUS$210 million and bringing in the strategic investors, Temasek, Highlight Capital (HLC), and True Light. Following this transact...
Viva Biotech (1873.HK) Announces 2023 Interim Results：Solid Growth in Main Business, Significant Rebound in Profitability
Highlights of the Interim Results as of June 30, 2023: * Revenue reached RMB1,142.2 million, representing a year-on-year increase of approximately 3.0% * Gross profit amounted to RMB406.0 million, representing a year-on-year increase of approximately 17.7% * Adjusted Non-IFRS net profit amo...
Latest Updates of 7 Viva's Portfolio Companies
HONG KONG, July 28, 2023 /PRNewswire/ -- In the face of ever-changing circumstances, technological innovation remains the eternal driving force behind the long-term growth of biopharmaceutical companies. It continuously breathes life into these enterprises, enabling them to successfully transitio...
Viva Biotech's Portfolio Company Riparian Pharmaceuticals Announces Exclusive License Agreement and Research Agreement with Pfizer for Novel Cardiovascular Programs
WATERTOWN, Mass., July 20, 2023 /PRNewswire/ -- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases. Riparian today announced it has entered into an exclusive license agreement and research a...
Viva Biotech's Portfolio Company DTx Pharma Reached the Acquisition Agreement with Novartis
* DTx Pharma's Fatty Acid Ligand Conjugated Oligonucleotide (FALCON™) platform facilitates extra-hepatic delivery of siRNA therapeutics * Acquisition includes DTx-1252 with the potential to deliver a transformative medicine to Charcot-Marie-Tooth Disease Type 1A (CMT1A) patients * Acquisitio...
Viva Biotech Announced Strategic Investors with an Investment of Approximately US$ 210 Million
HONG KONG, June 16, 2023 /PRNewswire/ -- On June 11, 2023, Viva Biotech Holdings Group (1873.HK) announced that Viva Shanghai, the primary entity for Viva Biotech's CRO business, successfully raised nearlyUS$ 150 million through the transfer of approximately 24% of its equity interest to Temasek,...
Viva Biotech's Recent Conferences & Events Review
HONG KONG, May 5, 2023 /PRNewswire/ -- In April, Viva Biotech was invited to attend 2022 SAPA-China Annual Conference, 88th API China, Drug Discovery Chemistry, American Association for Cancer Research (AACR) Annual Meeting 2023, CPHI Japan 2023, PharmFuture 2023 Small Molecule Innovative Drug Fu...
Viva Biotech Announced 2022 Annual Results:
Revenue and Gross Profit with Steady Growth Competitive Advantages of One-stop Platform Continuously Demonstrating Financial highlights of the year ended December 31, 2022: * Revenue amounted to RMB2,379.6 million, representing a year-on-year (YoY) increase of 13.1% * Gross profit amounted to...
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
JERSEY CITY, N.J. and SHANGHAI, Dec. 2, 2022 /PRNewswire/ -- Focus-X Therapeutics (referred to here as "Focus-X"), a nuclide drug company that was invested in and incubated by Viva Biotech, successfully reached an acquisition agreement with Full-Life Technologies Co., Ltd. (referred to here as "...
Viva Biotech Announced 2022 Interim Results
Order Backlog Expected to Empower Future Growth with Increasing Long-term Competitive Advantages Financial Highlights for the 6 months ended June 30, 2022: * Revenue amounted to RMB1,108.7 million, representing a year-on-year ("YoY") increase of 8.0% * Gross profit amounted to RMB345.0 milli...
Viva Biotech Successfully Held The 3rd Annual Partnership Summit
SHANGHAI, June 23, 2022 /PRNewswire/ -- June 16th-20th, 2022 (Beijing time), Viva Biotech 2022 Partnership Summit was successfully held. Over 300 attendees joined the Summit, including founders from portfolio companies, representatives from global investment institutions, R&D heads from pharmaceu...
